🩺Eating Disorder Cases Up 71% Since 1990, GLP-1 Drugs Add New Risk

Your GLP-1 patients might need a screening question

Eating disorders are getting more common, and the newest weight-loss drugs may be making it worse. Global incidence of anorexia nervosa and bulimia nervosa rose 71% between 1990 and 2023, and GLP-1 medications are now part of that story. Why should you care? Because the people building apps, clinical tooling, and fitness products sit right where this lands. A GLP-1 prescription can be the trigger for someone already predisposed, and anorexia patients can lose weight faster and more extremely on these drugs. If your product tracks weight, dosing, or calorie goals, it needs guardrails and a way to flag concerning behavior. The numbers are blunt. An estimated 18.1 million people had anorexia or bulimia in 2023, and that could climb to 21.8 million by 2050. US hospitalizations for eating disorders doubled between 2018 and 2020. Meanwhile a Gallup survey found 15% of Americans had used a GLP-1 drug for weight loss, and about 10% of people with eating disorders appeared to misuse them. What to watch: how regulators and prescribers respond to misuse data, and whether platforms change recommendation logic. The research is correlational for social media, so treat those links as signals, not proof.